AUTOIMMUNE HAEMOLYTIC ANAEMIA DURING BENDAMUSTINE PLUS RITUXIMAB TREATMENT IN CLL PATIENTS

被引：0
|
作者：
Laurenti, L. [1 ]
Autore, F. [1 ]
Innocenti, I. [1 ]
D'Arena, G. [2 ]
Coscia, M. [3 ]
Mondello, P. [4 ]
Bellesi, S. [1 ]
Efremov, D. [5 ]
Sica, S. [1 ]
Mauro, F. R. [6 ]
机构：
[1] Univ Cattolica Sacro Cuore, A Gemelli Policlin, I-00168 Rome, Italy
[2] IRCCS Ctr Riferimento Oncol Basilicata, Rionero In Vulture, PZ, Italy
[3] AO Citta Salute & Sci S Giovanni Battista, Turin, Italy
[4] Univ Messina, Dept Human Pathol, Messina, Italy
[5] Monterotondo Scalo, Int Ctr Genet Engn & Biotechnol, Rome, Italy
[6] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, I-00185 Rome, Italy
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P197
引用
收藏
页码：133 / 133
页数：1
相关论文
共 50 条
  • [41] Successful treatment of refractory autoimmune haemolytic anaemia in a post-unrelated bone marrow transplant paediatric patient with rituximab
    Hongeng, S
    Tardtong, P
    Worapongpaiboon, S
    Ungkanont, A
    Jootar, S
    BONE MARROW TRANSPLANTATION, 2002, 29 (10) : 871 - 872
  • [42] Successful treatment of refractory autoimmune haemolytic anaemia in a post-unrelated bone marrow transplant paediatric patient with rituximab
    S Hongeng
    P Tardtong
    S Worapongpaiboon
    A Ungkanont
    S Jootar
    Bone Marrow Transplantation, 2002, 29 : 871 - 872
  • [43] Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202
    Ruppert, Amy S.
    Booth, Allison M.
    Ding, Wei
    Bartlett, Nancy L.
    Brander, Danielle M.
    Coutre, Steven
    Brown, Jennifer R.
    Nattam, Sreenivasa
    Larson, Richard A.
    Erba, Harry
    Litzow, Mark
    Owen, Carolyn
    Kuzma, Charles S.
    Abramson, Jeremy S.
    Little, Richard F.
    Smith, Scott E.
    Stone, Richard M.
    Byrd, John C.
    Mandrekar, Sumithra J.
    Woyach, Jennifer A.
    LEUKEMIA, 2021, 35 (10) : 2854 - 2861
  • [44] Abnormalities of membrane protein composition in patients with autoimmune haemolytic anaemia
    DeAngelis, V
    DeMatteis, MC
    Cozzi, MR
    Fiorin, F
    Pradella, P
    Steffan, A
    Vettore, L
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 95 (02) : 273 - 277
  • [45] Metabolomic profile in patients with primary warm autoimmune haemolytic anaemia
    Rabelo, Iara B.
    Chiba, Akemi K.
    Moritz, Elyse
    D'Amora, Paulo
    Silva, Ismael Dale C. G.
    Rodrigues, Celso A.
    Barros, Melca M. O.
    Bordin, Jose O.
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 (01) : 140 - 149
  • [46] Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202
    Amy S. Ruppert
    Allison M. Booth
    Wei Ding
    Nancy L. Bartlett
    Danielle M. Brander
    Steven Coutre
    Jennifer R. Brown
    Sreenivasa Nattam
    Richard A. Larson
    Harry Erba
    Mark Litzow
    Carolyn Owen
    Charles S. Kuzma
    Jeremy S. Abramson
    Richard F. Little
    Scott E. Smith
    Richard M. Stone
    John C. Byrd
    Sumithra J. Mandrekar
    Jennifer A. Woyach
    Leukemia, 2021, 35 : 2854 - 2861
  • [47] T helper cell cytokines in patients with autoimmune haemolytic anaemia
    Dempster, AM
    Hall, AM
    Vickers, MA
    Barker, RN
    IMMUNOLOGY, 2005, 116 : 50 - 50
  • [48] RITUXIMAB PLUS BENDAMUSTINE IN ELDERLY PATIENTS AFFECTED BY RELAPSED OR REFRACTORY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Lucania, A.
    Villa, M. R.
    Izzo, G. Nitrato
    Improta, S.
    Mastrullo, L.
    HAEMATOLOGICA, 2014, 99 : 591 - 591
  • [49] Childhood refractory autoimmune haemolytic anaemia: Is there a role for anti-CD20 therapy (rituximab)?
    Mc Mahon, C
    Babu, L
    Hodgson, A
    Hayat, A
    Connell, NO
    Smith, OP
    BRITISH JOURNAL OF HAEMATOLOGY, 2002, 117 (02) : 480 - 482
  • [50] Direct antiglobulin test negative autoimmune haemolytic anaemia associated with fludarabine/cyclophosphamide/rituximab therapy
    Garratty, George
    Petz, Lawrence D.
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 139 (04) : 622 - 623
12345